Navigation Links
New Cardioprotective Drug Could Provide Boost For Post-Bypass,Surgery Heart Health

SOMERSET, N.J., April 5, 2007-- Stent thrombosis, restenosis and lifelong prescriptions. Millions of patients have discovered that the drug-coated stents used as part of their heart operations may be having more of a detrimental effect on their health than medical experts have ever publicly acknowledged. Recent articles in medical journals suggest that unless patients who receive drug-eluting stents continue to take blood thinners, they could more than double their risk of heart attack or death.

This emerging safety controversy around drug-coated stents has some experts predicting a resurgence in heart bypass operations. The bypass operations, although more invasive and dangerous, are believed to have longer lasting benefits compared to stents.

"Doctors have been less inclined to recommend bypass surgery for their patients because of the risk associated with the procedure, most notably post-operative heart attacks," stated Dr. Bob Harrington of Duke Clinical Research Institute. "Unfortunately there are currently no approved drugs to lessen that risk."

One company that could improve bypass outcomes for patients is Medicure, Inc. The company has developed a cardio-protective drug known as MC-1 that in recent clinical trails cut the threat of post-operative heart attacks in bypass patients nearly in half. Medicure's MC-1 is currently in a late-stage clinical trial and if successful could lead to its approval for sale in the U.S.

"MC-1 has the opportunity to be the first drug available to help the hundreds of thousands of patients undergoing bypass surgery every year," says Medicure CEO Dr. Albert D. Friesen.

For more information on this topic go to: http://www.medicure.com/mc_1.html(http://www.medicure.com/mc_1.html) or call 888.435.2220

# # #


'"/>




Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
4. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. XTL Provides Update on Phase I Clinical Trial of XTL-2125
9. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
10. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
11. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):